The Merck Accelerator Program 2019

MerckThe Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites events in Africa, startups can find their perfect fit and connect to the global network for collaboration. Are you ready to partner with Merck?

Applications for the HQ Program are open! From July until the end of September Merck will be looking for startups to join the Accelerator Program in Darmstadt. Come to the headquarters to connect with worldwide decision-makers and win Merck as your business partner. Take your chance to extend your stay in the Innovation Hub in China and succeed in accessing the Chinese market.

What are the key benefits of Merck Accelerator?

  • Partnership: Merck Accelerator is looking for strong business alliances and want to partner up with promising startups to build sustainable and successful business relationships.
  • Mentoring: Receive mentoring from members of Senior Management and Merck global network of over 50,000 experts. Dive deep into mentoring sessions and workshops.
  • Curriculum: Benefit from tailored coaching sessions and workshops provided by the Innovator Academy.
  • Funding: Kick off your startup project with seed funding of up to €50,000 and access Merck Accelerator investor network.
  • Access to the Chinese Market: Selected startups will also have the chance to extend their stay by joining our China Innovation Hub
  • Community: Team up with others facing the same challenges and build lifelong relationships.

A bustling city in the heart of Germany

The Rhine-Main region is a culturally and economically vibrant region in Hesse, Germany. It is home to the metropolises of Frankfurt and the state capitals of Wiesbaden and Mainz. Darmstadt is a city well-accustomed to witnessing big developments in science and high-tech. The city is home to several renowned scientific and technological institutions, as well as many great discoveries in chemistry and physics. Darmstadt has also been named "Digital City" and "City of the Future" in recognition of its status as Germany's most promising digital location of the future.

Are you ready to access the Chinese market?

Following the HQ program, selected startups could qualify to participate in the Merck Accelerator extension in China. They will get guidance to access the Chinese Market, as well as insights on the local regulatory affairs and customers-base. The HQ Accelerator Program is therefore complemented by a tailored Program in the China Innovation hub in Shanghai in which the startups will be able to choose curriculum and mentoring subjects, as well as trainings for localizing their business model in China and developing partnership strategies.

Start your journey in the Merck headquarter in Darmstadt, Germany and use your chance to also get access to the Chinese market via Merck.

When & Where

The HQ Accelerator program application phase is running from July until September 2018.
The HQ Accelerator intake will take place from January until April 2019 (3 months at the Innovation Center).

Are you a startup operating in the fields of healthcare, performance materials, life sciences, and other related business fields?

Then apply now via the web link below:
https://www.f6s.com/acceleratorprogram2019

Application submission deadline: September 30th 2018

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...